Skip to main content
SpringerLink
Log in

Long-term GH treatment of GH-deficient adults: Comparison between one and two daily injections

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The physiological pulsatile secretion of GH in humans might be important for the metabolic effects of GH. In the treatment of GH-deficient (GHD) patients, the most common regimen is a single sc injection at bedtime. It has not been completely established if this is the optimal mode of GH administration during long-term GH treatment. The aim of the present study was to evaluate the metabolic effects of two different GH replacement regimens comparing one to two daily injections. Eight men and six women, 42–78 yr old, with verified severe GHD, participated. Patients were matched for gender, age and body mass index (BMI) and were randomized to GH therapy (one or two injections daily) for 12 months. GH doses were individually titrated to IGF-I levels of age-matched controls. IGF-I, glucose, insulin, oral glucose tolerance test (OGTT), cholesterol, triglycerides, lipoproteins, including size fractionation with fast performance liquid chromatography, BMI and body composition were analyzed. After 12 months the median GH dose was 0.45 mg (range 0.25–0.50 mg) in both groups. Body fat had decreased by 20% (p<0.05) in the group receiving one daily GH injection. There were no differences between the two treatment groups in indices of carbohydrate or lipid metabolism. The administration of GH divided into two daily doses offered no major advantage as compared to the more convenient single injection in the evening. The GH-induced reduction in body fat occurred independently from changes in serum lipids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest 1968, 47: 2079–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Plotnick LP, Thompson RG, Kowarski A, de Lacerda L, Migeon CJ, Blizzard RM. Circadian variation of integrated concentration of growth hormone in children and adults. J Clin Endocrinol Metab 1975, 40: 240–7.

    Article  CAS  PubMed  Google Scholar 

  3. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998, 19: 717–97.

    CAS  PubMed  Google Scholar 

  4. Edén S, Jansson JO, Oscarsson J. Sexual dimorphism of growth hormone secretion. In: Isaksson O, Binder C, Hall K, Hokfelt B eds. Growth hormone-basic and clinical aspects. Amsterdam: Elsevier Science Publishers BV. 1987, 129–53.

    Google Scholar 

  5. Jansson JO, Albertsson-Wikland K, Eden S, Thorngren KG, Isaksson O. Effect of frequency of growth hormone administration on longitudinal bone growth and body weight in hypophysectomized rats. Acta Physiol Scand 1982, 114: 261–5.

    Article  CAS  PubMed  Google Scholar 

  6. Albertsson-Wikland K, Westphal O, Westgren U. Daily subcutaneous administration of human growth hormone in growth hormone deficient children. Acta Paediatr Scand 1986, 75: 89–97.

    Article  CAS  PubMed  Google Scholar 

  7. Christiansen JS, Orskov H, Binder C, Kastrup KW. Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children. Acta Endocrinol (Copenh) 1983, 102: 6–10.

    CAS  Google Scholar 

  8. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998, 83: 382–95.

    Article  CAS  PubMed  Google Scholar 

  9. Kastrup KW, Christiansen JS, Andersen JK, Orskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh) 1983, 104: 148–52.

    CAS  Google Scholar 

  10. Salomon F, Cuneo RC. Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797–803.

    Article  CAS  PubMed  Google Scholar 

  11. Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989, 1: 1221–5.

    Article  CAS  PubMed  Google Scholar 

  12. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002, 87: 2121–7.

    Article  CAS  PubMed  Google Scholar 

  13. Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short- and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995, 80: 356–63.

    CAS  PubMed  Google Scholar 

  14. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 1990, 70: 207–14.

    Article  CAS  PubMed  Google Scholar 

  15. Jorgensen JO, Moller N, Lauritzen T, Christiansen JS. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 1990, 70: 1616–23.

    Article  CAS  PubMed  Google Scholar 

  16. Tauber M, De Bouet Du Portal H, Sallerin-Caute B, Rochiccioli P, Bastide R. Differential regulation of serum growth hormone (GH)-binding protein during continuous infusion versus daily injection of recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 1993, 76: 1135–9.

    CAS  PubMed  Google Scholar 

  17. Laursen T, Jorgensen JO, Christiansen JS. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin Endocrinol (Oxf) 1994, 41: 337–43.

    Article  CAS  Google Scholar 

  18. Laursen T, Gravholt CH, Heickendorff L, et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J Clin Endocrinol Metab 2001, 86: 1222–8.

    CAS  PubMed  Google Scholar 

  19. Johansson JO, Wiren L, Oscarsson J, Bengtsson BA, Johannsson G. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections. Growth Horm IGF Res 2003, 13: 306–15.

    Article  CAS  PubMed  Google Scholar 

  20. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, Corcoy R. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000, 43: 1507–11.

    Article  CAS  PubMed  Google Scholar 

  21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  CAS  PubMed  Google Scholar 

  22. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47: 1643–9.

    Article  CAS  PubMed  Google Scholar 

  23. Tothill P, Avenell A, Love J, Reid DM. Comparisons between Hologic, Lunar and Norland dual-energy X-ray absorptiometers and other techniques used for whole-body soft tissue measurements. Eur J Clin Nut 1994, 48: 781–94.

    CAS  Google Scholar 

  24. Anonymous Assessment of Fracture Risk and it’s application to screening for postmenopausal osteoporosis. WHO Technical Report series, Geneva, 1994, p. 843.

  25. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991, 124: 620–9.

    CAS  Google Scholar 

  26. Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M. Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19–82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999, 84: 2013–9.

    CAS  PubMed  Google Scholar 

  27. Povoa G, Roovete A, Hall, K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984, 107: 563–70.

    CAS  Google Scholar 

  28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499–502.

    CAS  PubMed  Google Scholar 

  29. Parini P, Johansson L, Broijersen A, Angelin B, Rudling M. Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 2006, 36: 98–104.

    Article  CAS  PubMed  Google Scholar 

  30. Axelson M, Aly A, Sjovall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988, 239: 324–8.

    Article  CAS  PubMed  Google Scholar 

  31. Axelson M, Bjorkhem I, Reihner E, Einarsson K. The plasma level of 7 alpha-hydroxy-4-cholesten-3-one reflects the activity of hepatic cholesterol 7 alpha-hydroxylase in man. FEBS Lett 1991, 284: 216–8.

    Article  CAS  PubMed  Google Scholar 

  32. Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. J Lipid Res 2003, 44: 859–66.

    Article  CAS  PubMed  Google Scholar 

  33. Sauter G, Berr F, Beuers U, Fischer S, Paumgartner G. Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 1996, 24: 123–6.

    CAS  PubMed  Google Scholar 

  34. Oscarsson J, Johannsson G, Johansson JO, Lundberg PA, Lindstedt G, Bengtsson BA. Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults. Clin Endocrinol (Oxf) 1997, 46: 63–8.

    Article  CAS  Google Scholar 

  35. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 1993, 13: 296–301.

    Article  CAS  PubMed  Google Scholar 

  36. Hwu CM, Kwok CF, Lai TY, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997, 82: 3285–92.

    CAS  PubMed  Google Scholar 

  37. Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995, 15: 2142–50.

    Article  CAS  PubMed  Google Scholar 

  38. Oscarsson J, Ottosson M, Johansson JO, et al. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults. II. Effects on serum lipoproteins and lipoprotein and hepatic lipase activity. Metabolism 1996, 45: 370–7.

    Article  CAS  PubMed  Google Scholar 

  39. Fernholm R, Bramnert M, Hägg E, et al. Growth hormone replacement therapy improves body composition in elderly patients with pituitary disease. J Clin Endocrinol Metab 2000, 85: 4104–12.

    CAS  PubMed  Google Scholar 

  40. Benbassat CA, Wasserman M, Laron Z. Changes in bone mineral density after discontinuation and early reinstitution of growth hormone (GH) in patients with childhood-onset GH deficiency. Growth Horm IGF Res 1999, 9: 290–5.

    Article  CAS  PubMed  Google Scholar 

  41. Olivecrona H, Ericsson S, Angelin B. Growth hormone treatment does not alter biliary lipid metabolism in healthy adult men. J Clin Endocrinol Metab 1995, 80: 1113–7.

    CAS  PubMed  Google Scholar 

  42. Lind S, Rudling M, Ericsson S, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol 2004, 24: 349–56.

    Article  CAS  PubMed  Google Scholar 

  43. Leonsson M, Oscarsson J, Bosaeus I, et al. Growth hormone (GH) therapy in GH-deficient adults influences the response to a dietary load of cholesterol and saturated fat in terms of cholesterol synthesis, but not serum low density lipoprotein cholesterol levels. J Clin Endocrinol Metab 1999, 84: 1296–303.

    CAS  PubMed  Google Scholar 

  44. Rudling M, Parini P, Angelin B. Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat. J Clin Invest 1997, 99: 2239–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Parini P, Angelin B, Rudling M. Cholesterol and lipoprotein metabolism in aging: reversal of hypercholesterolemia by growth hormone treatment in old rats. Arterioscler Thromb Vasc Biol 1999, 19: 832–9.

    Article  CAS  PubMed  Google Scholar 

  46. Rudling M, Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J 2001, 15: 1350–6.

    Article  CAS  PubMed  Google Scholar 

  47. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992, 89: 6983–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Solna, 171 76, Stockholm, Sweden

    C. Höybye

  2. Department of Endocrinology, Metabolism and Diabetology, Karolinska University Hospital, Huddinge, Stockholm, Sweden

    M. Rudling

Authors
  1. C. Höybye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Rudling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Höybye.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höybye, C., Rudling, M. Long-term GH treatment of GH-deficient adults: Comparison between one and two daily injections. J Endocrinol Invest 29, 950–956 (2006). https://doi.org/10.1007/BF03349206

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349206

Key-words

Search

Navigation